Safe Harbor Provision + This communication contains forward-looking statements. These statements
are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include, without limitation, statements about the proposed combination of Upjohn Inc. (Upjohn),
a wholly owned subsidiary of Pfizer Inc. (Pfizer), and Mylan N.V. (Mylan), which will immediately follow the proposed separation of the Upjohn business from Pfizer (the proposed transaction), the expected
timetable for completing the proposed transaction, the benefits and synergies of the proposed transaction, future opportunities for the combined company and products and any other statements regarding Pfizers, Mylans and Upjohns
future operations, financial or operating results, capital allocation, dividend policy, debt ratio, anticipated business levels, future earnings, planned activities, anticipated growth, market opportunities, strategies, competitions, and other
expectations and targets for future periods. Forward-looking statements may often be identified by the use of words such as will, may, could, should, would, project,
believe, anticipate, expect, plan, estimate, forecast, potential, intend, continue, target, outlook and variations of
these words or comparable words. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause
or contribute to such differences include, but are not limited to: the parties ability to meet expectations regarding the timing, completion and accounting and tax treatments of the proposed transaction; changes in relevant tax and other laws;
the parties ability to consummate the proposed transaction; the conditions to the completion of the proposed transaction, including receipt of approval of Mylans shareholders, not being satisfied or waived on the anticipated timeframe or
at all; the regulatory approvals required for the proposed transaction not being obtained on the terms expected or on the anticipated schedule or at all; inherent uncertainties involved in the estimates and judgments used in the preparation of
financial statements and the providing of estimates of financial measures, in accordance with the accounting principles generally accepted in the United States of America (U.S. GAAP) and related standards, or on an adjusted basis (Non-GAAP measures); the integration of Mylan and Upjohn being more difficult, time consuming or costly than expected; Mylans and Upjohns failure to achieve expected or targeted future
financial and operating performance and results; the possibility that the combined company may be unable to achieve expected benefits, synergies and operating efficiencies in connection with the proposed transaction within the expected time frames
or at all or to successfully integrate Mylan and Upjohn; customer loss and business disruption being greater than expected following the proposed transaction; the retention of key employees being more difficult following the proposed transaction;
Mylan and Upjohns capacity to bring new products to market, including but not limited to where it uses its business judgment and decides to manufacture, market and/or sell products directly or through third parties, notwithstanding the fact
that allegations of patent infringement(s) have not been finally resolved by the courts (i.e., an at-risk launch); the scope, timing and outcome of any ongoing legal proceedings and the impact of
such proceedings on Mylans and Upjohns consolidated financial condition, results of operations and/or cash flows; Mylans and Upjohns ability to protect their respective intellectual property and preserve their respective
intellectual property rights; the effect of any changes in customer and supplier relationships and customer purchasing patterns; the ability to attract and retain key personnel; changes in third-party relationships; the impacts of competition;
changes in the economic and financial conditions of the business of Mylan or Upjohn; and uncertainties and matters beyond the control of management and other factors described under Risk Factors in each of Pfizers and Mylans
Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission (SEC). You can access Pfizers
or Mylans filings with the SEC through the SEC website at www.sec.gov or through Pfizers or Mylans website, and Pfizer and Mylan strongly encourage you to do so. Except as required by applicable law, Pfizer, Mylan or Upjohn
undertake no obligation to update any statements herein for revisions or changes after the date of this communication. 1